Myasthenia gravis is a long-term autoimmune disease characterized by the destruction of nerve-muscle
communication by antibodies, which leaves the skeletal muscles feeble. The voluntary muscles in the body are
impacted by myasthenia gravis, particularly those that regulate the mouth, throat, eyes, and limbs. There are 150–200
cases of Myasthenia gravis for every million people. This is the prevalence rate. Five main categories comprise
clinical features. Breathing difficulties, drooping eyelids, and impaired vision are symptoms. Its causes stem from
damage to nerve signals that are linked to muscles. Stress, fatigue, surgery, and pregnancy increase the risk of
Myasthenia gravis. Diagnosis tests that are done for Myasthenia gravis. Decreased availability of receptors for
activation leads to voluntary muscular weakness that gets worse with continuous use. Complications that cause
respiratory failure, dysphagia, and, due to overdose, cholinergic crises blood test of antibodies, pharmacological test,
Icepack test, repetitive nerve stimulation, edrophoniurm test, thymus imaging, serological test, and electrodiagnostic
studies. Treatments given for Myasthenia gravis are corticosteroids, immunosuppressants, acetylcholinesterase
inhibitors, thymectomy, plasmapheresis, intravenous immunoglobulins. In pregnancy, plasmapheresis is given to
treat. Steroids and anticholinesterase drugs have not been demonstrated to significantly increase the incidence of
plasmapheresis.